aibioAlto Neuroscience IPO securities class action dismissed with leave to amend
Tickers ANRO
A federal court in California dismissed the securities class action over Alto Neuroscience's ALTO-100 disclosures on August 7, 2026, and gave the plaintiffs leave to file a third amended complaint. A related derivative action has been stayed.
Key facts
- Company
- Alto Neuroscience, Inc. (NYSE: ANRO)
- News type
- Legal
- Primary source
- Alto Neuroscience 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)
Alto Neuroscience, Inc. (NYSE: ANRO) said in its 10-Q filed August 12, 2026 that a federal court granted its motion to dismiss a securities class action on August 7, 2026 and allowed the plaintiffs to file a third amended complaint. The defendants are Alto, certain executive officers and certain current and former directors. A purported stockholder filed the case, No. 3:25-cv-06105, on July 21, 2025 in the U.S. District Court for the Northern District of California. The 10-Q names none of the individuals.
A consolidated derivative action, In re Alto Neuroscience, Inc. Derivative Litigation, Lead Case No. 5:25-cv-07144-NW, makes related claims on the company's behalf against certain executive officers and certain current and former directors. It is stayed while the class action is pending.
The claims
The complaint is a putative class action under the Securities Act of 1933 and the Exchange Act. The Securities Act claims concern Alto's initial public offering in February 2024. The proposed classes are purchasers of Alto stock under or traceable to the IPO, and purchasers between March 18, 2024 and October 22, 2024, inclusive. The plaintiff alleges that the offering documents and later disclosures contained materially false and misleading statements, and left out material facts, about the prospects of ALTO-100. The plaintiff seeks unspecified damages, interest, fees and costs.
The derivative plaintiffs allege breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets and violations of federal securities laws. They rely on the same facts and seek unspecified damages, interest, fees and costs.
Who the individuals are
Alto's proxy statement filed April 1, 2025 lists Amit Etkin, M.D., Ph.D., as president, chief executive officer and chair, Christopher Nixon Cox as lead independent director, and Andrew Dreyfus, Gwill York and Husseini Manji, M.D., as directors. It says the board then had seven members and that two Class I directors were not standing for re-election. Nicholas Smith is chief financial officer and chief business officer. The filings do not say which of these people are defendants.
Alto's annual report for 2024 says the IPO sold 9,246,000 shares at $16.00 each. Jefferies LLC, Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C. were joint lead book-running managers, and Robert W. Baird & Co. Incorporated was lead manager. The 10-Q does not say any underwriter is a defendant.
Where it stands
The plaintiff filed an amended complaint on January 23, 2026 and a second amended complaint on April 6, 2026. Alto moved to dismiss on May 5, 2026. The court granted the motion on August 7, 2026 and gave the plaintiffs leave to file a third amended complaint. The 10-Q does not give a deadline for that filing.
The derivative action was stayed on January 14, 2026 until the motion to dismiss in the class action is resolved. Alto says it believes the allegations in the class action and the derivative claims lack merit.
What the company says
Alto has recorded no liability for these lawsuits because it does not believe an unfavorable outcome is probable or estimable. It also indemnifies its directors and officers who serve at its request. The 10-Q says the maximum exposure under those arrangements was unknown at June 30, 2026, and that it does not expect to recognize significant losses from them. The 10-Q does not say how much insurance coverage applies.
The drug at the center
The annual report says that in October 2024 Alto's Phase 2b trial of ALTO-100 in patients with major depressive disorder did not meet its primary endpoint. That failure falls at the end of the proposed class period. Alto's losses have grown since: a net loss of $63.2 million for 2025, with $51.8 million used in operations, and a net loss of $27,638 thousand for the second quarter of 2026, against $17,706 thousand a year earlier.